Cargando…
(18)F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies
Among individuals with dementia with Lewy bodies, pathologic correlates of clinical course include the presence and extent of coexisting Alzheimer’s pathology and the presence of transitional or diffuse Lewy body disease. The objectives of this study are to determine (i) whether (18)F-fluorodeoxyglu...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293797/ https://www.ncbi.nlm.nih.gov/pubmed/32566926 http://dx.doi.org/10.1093/braincomms/fcaa040 |
_version_ | 1783546363135393792 |
---|---|
author | Graff-Radford, Jonathan Lesnick, Timothy G Savica, Rodolfo Chen, Qin Ferman, Tanis J Przybelski, Scott A Jones, David T Senjem, Matthew L Gunter, Jeffrey L Kremers, Walter K Jack, Clifford R Lowe, Val J Petersen, Ronald C Knopman, David S Boeve, Bradley F Murray, Melissa E Dickson, Dennis W Kantarci, Kejal |
author_facet | Graff-Radford, Jonathan Lesnick, Timothy G Savica, Rodolfo Chen, Qin Ferman, Tanis J Przybelski, Scott A Jones, David T Senjem, Matthew L Gunter, Jeffrey L Kremers, Walter K Jack, Clifford R Lowe, Val J Petersen, Ronald C Knopman, David S Boeve, Bradley F Murray, Melissa E Dickson, Dennis W Kantarci, Kejal |
author_sort | Graff-Radford, Jonathan |
collection | PubMed |
description | Among individuals with dementia with Lewy bodies, pathologic correlates of clinical course include the presence and extent of coexisting Alzheimer’s pathology and the presence of transitional or diffuse Lewy body disease. The objectives of this study are to determine (i) whether (18)F-fluorodeoxyglucose PET signature patterns of dementia with Lewy bodies are associated with the extent of coexisting Alzheimer’s pathology and the presence of transitional or diffuse Lewy body disease and (ii) whether these (18)F-fluorodeoxyglucose pattern(s) are associated with clinical course in dementia with Lewy bodies. Two groups of participants were included: a pathology-confirmed subset with Lewy body disease (n = 34) and a clinically diagnosed group of dementia with Lewy bodies (n = 87). A subset of the clinically diagnosed group was followed longitudinally (n = 51). We evaluated whether (18)F-fluorodeoxyglucose PET features of dementia with Lewy bodies (higher cingulate island sign ratio and greater occipital hypometabolism) varied by Lewy body disease subtype (transitional versus diffuse) and Braak neurofibrillary tangle stage. We investigated whether the PET features were associated with the clinical trajectories by performing regression models predicting Clinical Dementia Rating Scale Sum of Boxes. Among autopsied participants, there was no difference in cingulate island sign or occipital hypometabolism by Lewy body disease type, but those with a lower Braak tangle stage had a higher cingulate island sign ratio compared to those with a higher Braak tangle stage. Among the clinically diagnosed dementia with Lewy bodies participants, a higher cingulate island ratio was associated with better cognitive scores at baseline and longitudinally. A higher (18)F-fluorodeoxyglucose PET cingulate island sign ratio was associated with lower Braak tangle stage at autopsy, predicted a better clinical trajectory in dementia with Lewy body patients and may allow for improved prognostication of the clinical course in this disease. |
format | Online Article Text |
id | pubmed-7293797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72937972020-06-17 (18)F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies Graff-Radford, Jonathan Lesnick, Timothy G Savica, Rodolfo Chen, Qin Ferman, Tanis J Przybelski, Scott A Jones, David T Senjem, Matthew L Gunter, Jeffrey L Kremers, Walter K Jack, Clifford R Lowe, Val J Petersen, Ronald C Knopman, David S Boeve, Bradley F Murray, Melissa E Dickson, Dennis W Kantarci, Kejal Brain Commun Original Article Among individuals with dementia with Lewy bodies, pathologic correlates of clinical course include the presence and extent of coexisting Alzheimer’s pathology and the presence of transitional or diffuse Lewy body disease. The objectives of this study are to determine (i) whether (18)F-fluorodeoxyglucose PET signature patterns of dementia with Lewy bodies are associated with the extent of coexisting Alzheimer’s pathology and the presence of transitional or diffuse Lewy body disease and (ii) whether these (18)F-fluorodeoxyglucose pattern(s) are associated with clinical course in dementia with Lewy bodies. Two groups of participants were included: a pathology-confirmed subset with Lewy body disease (n = 34) and a clinically diagnosed group of dementia with Lewy bodies (n = 87). A subset of the clinically diagnosed group was followed longitudinally (n = 51). We evaluated whether (18)F-fluorodeoxyglucose PET features of dementia with Lewy bodies (higher cingulate island sign ratio and greater occipital hypometabolism) varied by Lewy body disease subtype (transitional versus diffuse) and Braak neurofibrillary tangle stage. We investigated whether the PET features were associated with the clinical trajectories by performing regression models predicting Clinical Dementia Rating Scale Sum of Boxes. Among autopsied participants, there was no difference in cingulate island sign or occipital hypometabolism by Lewy body disease type, but those with a lower Braak tangle stage had a higher cingulate island sign ratio compared to those with a higher Braak tangle stage. Among the clinically diagnosed dementia with Lewy bodies participants, a higher cingulate island ratio was associated with better cognitive scores at baseline and longitudinally. A higher (18)F-fluorodeoxyglucose PET cingulate island sign ratio was associated with lower Braak tangle stage at autopsy, predicted a better clinical trajectory in dementia with Lewy body patients and may allow for improved prognostication of the clinical course in this disease. Oxford University Press 2020-04-08 /pmc/articles/PMC7293797/ /pubmed/32566926 http://dx.doi.org/10.1093/braincomms/fcaa040 Text en © The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Article Graff-Radford, Jonathan Lesnick, Timothy G Savica, Rodolfo Chen, Qin Ferman, Tanis J Przybelski, Scott A Jones, David T Senjem, Matthew L Gunter, Jeffrey L Kremers, Walter K Jack, Clifford R Lowe, Val J Petersen, Ronald C Knopman, David S Boeve, Bradley F Murray, Melissa E Dickson, Dennis W Kantarci, Kejal (18)F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies |
title |
(18)F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies |
title_full |
(18)F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies |
title_fullStr |
(18)F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies |
title_full_unstemmed |
(18)F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies |
title_short |
(18)F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies |
title_sort | (18)f-fluorodeoxyglucose positron emission tomography in dementia with lewy bodies |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293797/ https://www.ncbi.nlm.nih.gov/pubmed/32566926 http://dx.doi.org/10.1093/braincomms/fcaa040 |
work_keys_str_mv | AT graffradfordjonathan 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT lesnicktimothyg 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT savicarodolfo 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT chenqin 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT fermantanisj 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT przybelskiscotta 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT jonesdavidt 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT senjemmatthewl 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT gunterjeffreyl 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT kremerswalterk 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT jackcliffordr 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT lowevalj 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT petersenronaldc 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT knopmandavids 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT boevebradleyf 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT murraymelissae 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT dicksondennisw 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies AT kantarcikejal 18ffluorodeoxyglucosepositronemissiontomographyindementiawithlewybodies |